Actinogen Medical’s Xanamem: Promising Results from XanaCIDD Phase 2a TrialActinogen Medical (ASX: ACW) has announced the results of its XanaCIDD phase 2a trial, revealing significant advancements in treating major…Aug 14Aug 14
Actinogen Medical (ASX: ACW) to Become an Important Player in the Alzheimers MarketIt is estimated that over 29,000 people will suffer from early-onset dementia in 2024, and by 2054, this figure will rise to almost 41,000…Jul 24Jul 24
OncoSil’s Milestones in Pancreatic Cancer Treatment: New Trial Patients, Treatment Milestone, and…New Hope for Pancreatic Cancer PatientsJul 5Jul 5
Actinogen Medical (ACW): Potential for Cognitive Improvement in Depression TreatmentActinogen Medical ($ACW) recently announced that results from their phase 2a trial investigating Xanamem for cognitive improvement in…Jul 43Jul 43
OncoSil Medical (ASX:OSL) Results of Annual General MeetingOn 29 November 2023, OncoSil Medical Ltd, a medical device company focusing on localised treatments for patients with locally advanced…Nov 29, 20235Nov 29, 20235
The Future of Healthcare Stocks: Key Predictions and StrategiesIn the complex world of investing, healthcare stocks are emerging as a compelling and resilient option. As global demographics evolve and…Oct 26, 2023Oct 26, 2023
Healthcare Stocks and the Aging Population: A Growing MarketThe world is undergoing a significant demographic shift, with the aging population emerging as a dominant force in today’s society. As…Oct 26, 2023Oct 26, 2023
Sustainable Healthcare: Investing in Companies with a PurposeIn a world that’s increasingly conscious of its environmental and social footprint, the healthcare industry has taken center stage as a…Oct 26, 2023Oct 26, 2023
Dividend-Yielding Healthcare Stocks: Building Income in Your PortfolioIn the world of investments, one goal stands out prominently for many: the pursuit of a steady income. Whether you’re a retiree looking to…Oct 20, 2023Oct 20, 2023